Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same

US6187306A · kind A · utility

Assignees

• THE JOHNS HOPKINS UNIVERSITY · US
• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Drew M. Pardoll · Silver Spring, US
• Elizabeth Jaffee · Timonium, US
• Adam Shultz Adler · Belmont, US
• Suzanne L. Topalian · Silver Spring, US
• Steven A. Rosenberg · Potomac, US

Key dates

• Filing date: Aug 5, 1997
• Grant date: Feb 13, 2001
• Expiry date: Aug 5, 2017

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/55522
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention pertains to a method of treating or protecting against melanoma that comprises (a) obtaining a melanoma cell line that expresses one or more shared immunodominant melanoma antigens, (b) modifying the melanoma cell line to render it capable of producing an increased level of a cytokine relative to the unmodified cell line, and (c) administering the melanoma cell line to a mammalian host that has melanoma or is at risk for developing melanoma. Preferably the melanoma cell line is allogeneic and is not MHC-matched to the host.